tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ASND Stock Latest News

Ascendis Pharma price target raised to $260 from $246 at BofA
The FlyAscendis Pharma price target raised to $260 from $246 at BofA
7d ago
ASND
Ascendis Pharma initiated with an Overweight at Barclays
PremiumThe Fly
Ascendis Pharma initiated with an Overweight at Barclays
9d ago
ASND
Looking for Exposure to UnitedHealth Stock (UNH) ahead of Q4 Earnings? Here’s How to Buy Without the Risk
PremiumMarket News
Looking for Exposure to UnitedHealth Stock (UNH) ahead of Q4 Earnings? Here’s How to Buy Without the Risk
11d ago
LLY
TMO
Ascendis Pharma rumor highlighted in Betaville blog
PremiumThe Fly
Ascendis Pharma rumor highlighted in Betaville blog
15d ago
ASND
Ascendis Pharma price target raised to $250 from $245 at RBC Capital
PremiumThe Fly
Ascendis Pharma price target raised to $250 from $245 at RBC Capital
17d ago
ASND
Ascendis Pharma price target raised to $330 from $322 at Wells Fargo
PremiumThe FlyAscendis Pharma price target raised to $330 from $322 at Wells Fargo
17d ago
ASND
Ascendis Pharma: Sustained Commercial Momentum and TransCon Pipeline Catalysts Underpin Buy Rating
Premium
Ratings
Ascendis Pharma: Sustained Commercial Momentum and TransCon Pipeline Catalysts Underpin Buy Rating
20d ago
ASND
Ascendis Pharma Grants New Employee Warrants, Updates Articles of Association
Premium
Company Announcements
Ascendis Pharma Grants New Employee Warrants, Updates Articles of Association
22d ago
6K
ASND
Ascendis Pharma: Vision 2030 Growth Story Driven by Yorvipath and Late‑Stage TransCon Pipeline Justifies Buy Rating
PremiumRatings
Ascendis Pharma: Vision 2030 Growth Story Driven by Yorvipath and Late‑Stage TransCon Pipeline Justifies Buy Rating
23d ago
ASND
Ascendis Pharma price target raised to $246 from $242 at BofA
PremiumThe Fly
Ascendis Pharma price target raised to $246 from $242 at BofA
25d ago
ASND
Ascendis Pharma Sets 2026 Milestones and Unveils $120 Million Share Buyback
PremiumCompany Announcements
Ascendis Pharma Sets 2026 Milestones and Unveils $120 Million Share Buyback
25d ago
6K
ASND
Ascendis Pharma sees FY25 revenue EUR 720M
PremiumThe Fly
Ascendis Pharma sees FY25 revenue EUR 720M
27d ago
ASND
Ascendis Pharma sees FY26 operating cash flow EUR 500M
PremiumThe FlyAscendis Pharma sees FY26 operating cash flow EUR 500M
27d ago
ASND
Ascendis Pharma announces $120M share repurchase program
Premium
The Fly
Ascendis Pharma announces $120M share repurchase program
27d ago
ASND
Ascendis Pharma: TransCon CNP/hGH Combo Data De-Risk Achondroplasia Program and Support Higher Target Price and Buy Rating
Premium
Ratings
Ascendis Pharma: TransCon CNP/hGH Combo Data De-Risk Achondroplasia Program and Support Higher Target Price and Buy Rating
28d ago
ASND
Ascendis Pharma price target raised to $322 from $297 at Wells Fargo
PremiumThe Fly
Ascendis Pharma price target raised to $322 from $297 at Wells Fargo
28d ago
ASND
Ascendis Pharma Posts Strong Year-Long Phase 2 COACH Data for TransCon CNP and hGH Combo in Achondroplasia
PremiumCompany Announcements
Ascendis Pharma Posts Strong Year-Long Phase 2 COACH Data for TransCon CNP and hGH Combo in Achondroplasia
28d ago
6K
ASND
Ascendis Pharma: Advancing Achondroplasia Combo Franchise and De-Risked Regulatory Path Support Buy Rating and $242 Target
PremiumRatings
Ascendis Pharma: Advancing Achondroplasia Combo Franchise and De-Risked Regulatory Path Support Buy Rating and $242 Target
28d ago
ASND
Ascendis Pharma announces topline results from Week 52 of COACH trial
PremiumThe Fly
Ascendis Pharma announces topline results from Week 52 of COACH trial
28d ago
ASND
Ascendis Pharma Advances Weekly Skytrofa Trial in Pediatric Growth Disorders: What Investors Should Watch
PremiumCompany AnnouncementsAscendis Pharma Advances Weekly Skytrofa Trial in Pediatric Growth Disorders: What Investors Should Watch
30d ago
ASND
TD Cowen Analyst Highlights Ascendis Pharma as Priority Healthcare Name With Buy Rating and Expected Outperformance
Premium
Ratings
TD Cowen Analyst Highlights Ascendis Pharma as Priority Healthcare Name With Buy Rating and Expected Outperformance
30d ago
ASND
Ascendis Pharma Ups Share Capital After Warrant Exercises in December 2025
Premium
Company Announcements
Ascendis Pharma Ups Share Capital After Warrant Exercises in December 2025
1M ago
6K
ASND

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >